All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
FDA approves subcutaneous daratumumab + Pd for the treatment of R/R MM
By Claire Baker
Bookmark this article
On July 9, 2021, the combination of subcutaneous daratumumab with pomalidomide and dexamethasone (Pd) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM).
The combination is indicated for the treatment of patients who have received ≥1 prior line of therapy, including lenalidomide and a proteasome inhibitor. Encouraging outcomes from the phase III APOLLO study (NCT03180736) aided the decision.
A request for approval of the combination was submitted to the FDA and European Medicines Agency (EMA) in November 2020, and the European Commission (EC) granted an extended marketing authorization to the combination in June 2021.
FDA. FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-pomalidomide-and-dexamethasone-multiple-myeloma. Accessed Jul 13, 2021. Published Jul 9, 2021.
Your opinion matters
60 votes - 51 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox